Biodexa Pharmaceuticals PLC
BDRX1.240USD
-0.060-4.62%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
7.68BMarket Cap
7.11P/E TTM
More Details of Biodexa Pharmaceuticals PLC Company
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Biodexa Pharmaceuticals PLC Info
Ticker SymbolBDRX
Company nameBiodexa Pharmaceuticals PLC
IPO dateDec 08, 2014
CEOStamp (Stephen A)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endDec 08
Address1 Caspian Point
CityABINGDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeCF10 4DQ
Phone4401235888300
Websitehttps://www.biodexapharma.com/
Ticker SymbolBDRX
IPO dateDec 08, 2014
CEOStamp (Stephen A)
Company Executives of Biodexa Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Belgium
381.00K
100.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Feb 2
Updated: Mon, Feb 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Brio Capital Management LLC
2.71%
Abbe (Richard)
0.39%
UBS Financial Services, Inc.
0.31%
GAMMA Investing LLC
0.29%
District 2 Capital LP
0.07%
Other
96.24%
Shareholders
Shareholders
Proportion
Brio Capital Management LLC
2.71%
Abbe (Richard)
0.39%
UBS Financial Services, Inc.
0.31%
GAMMA Investing LLC
0.29%
District 2 Capital LP
0.07%
Other
96.24%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
2.99%
Corporation
0.56%
Individual Investor
0.39%
Investment Advisor
0.31%
Hedge Fund
0.07%
Bank and Trust
0.03%
Research Firm
0.02%
Other
95.63%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
25
26.99K
4.95%
--
2025Q3
27
27.63K
4.95%
+6.43K
2025Q2
30
21.20K
5.92%
-17.70K
2025Q1
32
21.37K
16.41%
+10.40K
2024Q4
31
19.96K
16.99%
+9.20K
2024Q3
33
10.76K
4.86%
+5.02K
2024Q2
29
4.42K
2.68%
+1.32K
2024Q1
25
3.10K
2.07%
+2.75K
2023Q4
26
3.28K
0.82%
+3.22K
2023Q3
18
57.00
107.67%
+15.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Brio Capital Management LLC
16.77K
2.71%
+11.06K
+193.61%
Nov 14, 2024
Abbe (Richard)
2.43K
0.39%
+2.43K
--
Jul 19, 2024
GAMMA Investing LLC
1.78K
0.29%
+425.00
+31.43%
Dec 31, 2025
District 2 Capital LP
403.00
0.07%
-449.00
-52.70%
Nov 11, 2024
UBS Switzerland AG
6.92K
1.12%
+6.73K
+3379.90%
Sep 30, 2025
SBI Securities Co., Ltd.
115.00
0.02%
-452.00
-79.72%
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
5.00
0%
-2.00
-28.57%
Sep 30, 2025
Contravisory Investment Management, Inc.
--
0%
-4.00
-100.00%
Jun 30, 2025
Geode Capital Management, L.L.C.
--
0%
-8.00
-100.00%
Apr 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Date
Ex-dividend Date
Type
Ratio
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Mar 16, 2023
Merger
4→1
View more
